— Exact Sciences Corp. (NASDAQ: EXAS) reported Q4 2019 earnings of $0.54 per share, vs. a loss of $0.35 expected.
— Total revenues were $295.6 million, vs. $283 million expected.
— Screening revenues increased 60% to $229.4 million.
— Cologuard test volume rose 63% to 477,000.
— Average Cologuard recognized revenue per test was $481.
— Average Cologuard cost per test was $123.
— Precision Oncology proforma revenue increased 14% to $119.1 million.
— FY2020 consolidated revenue is expected to be $1.61-1.64 billion.
— FY2020 Screening revenue is expected to be $1.125-1.15 billion.
— FY2020 Precision Oncology revenue is expected to be $485-495 million.
— EXAS shares gained 1.2% immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Take-Two Interactive Software (TTWO) Earnings: 4Q24 Key Numbers
Take-Two Interactive Software, Inc. (NASDAQ: TTWO) reported net revenue of $1.40 billion for the fourth quarter of 2024, which was down 3% year-over-year. Net loss was $2.90 billion, or $17.02
Applied Materials (AMAT) Earnings: 2Q24 Key Numbers
Applied Materials, Inc. (NASDAQ: AMAT) reported revenue of $6.65 billion for the second quarter of 2024, which remained flat year-over-year. GAAP net income increased 9% to $1.72 billion and EPS
What to expect when Macy’s (M) reports its Q1 2024 earnings results
Shares of Macy’s, Inc. (NYSE: M) stayed green on Thursday. The stock has gained 23% over the past 12 months. The retailer is scheduled to report its first quarter 2024
